Heritable thrombophilia and hypofibrinolysis: Possible causes of retinal vein occlusion

Archives of Ophthalmology

Volumn 117, Issue 1, 1999, Pages 43-49

  Glueck, Charles J ^a   Bell, Howard ^a   Vadlamani, Lou ^a   Gupta, Arun ^b   Fontaine, Robert N ^b   Wang, Ping ^a   Stroop, Davis ^b   Gruppo, Ralph ^b  

^a JEWISH HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMINO ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; DNA; HOMOCYSTEINE; LIPOPROTEIN A; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; FLUORESCENCE ANGIOGRAPHY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; RISK FACTOR; THROMBOPHILIA;

EID: 0032960025     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.117.1.43     Document Type: Article

References (39)

1. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein thrombosis: a case-control study. Ophthalmology. 1992;99:509-514.
2. Dodson PM, Clough CG, Downes SM, Kritzinger EE. Does type II diabetes predispose to retinal vein occlusion? Eur J Ophthalmol. 1993;3:109-113.
3. Vine AK, Samama MM. The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. Surv Ophthalmol. 1993;37: 283-292.
4. Bandello F, Vigano D'Angelo S, Parlavecchia M, et al. Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost. 1994;72:39-43.
5. Acheson JF, Gregson RM, Merry P, Schulenburg WE. Vaso-occlusive retinopathy in the primary anti-phospholipid antibody syndrome. Eye. 1991;5(pt 1): 48-55.
6. Glacet-Bernard A, Bayani N, Chretien P, Cochard C, Lelong F, Coscas G. Anti-phospholipid antibodies in retinal vascular occlusions: a prospective study of 75 patients. Arch Ophthalmol. 1994;112:790-795.
7. Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol. 1993;115:162-167.
8. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol. 1996;80:203-208.
9. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol. 1996;80:200-202.
10. Scat Y, Morin Y, Morel C, Haut J. Retinal vein occlusion and resistance to activated protein C [in French]. J Fr Ophtalmol. 1995;18:758-762.
11. Graham SL, Goldberg I, Murray B, Beaumont P, Chong BH. Activated protein C resistance: low incidence in glaucomatous disc hemorrhage and central retinal vein occlusion. Aust N Z J Ophthalmol. 1996;24:199-205.
12. Gottlieb JL, Blice JP, Mestichelli B, Konkle BA, Benson WE. Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol. 1998;116:577-579.
13. Bertram B, Remky A, Arend O, Wolf S, Reim M. Protein C, protein S, and anti-thrombin III in acute ocular occlusive diseases. Ger J Ophthalmol. 1995;4: 332-335.
14. Glueck CJ, Freiberg RA, Crawford A, et al. Secondhand smoke, hypofibrinolysis, and Legg-Perthes disease. Clin Orthop. 1998;352:159-167.
15. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
16. Brandt G, Gruppo R, Glueck CJ, et al. Sensitivity, specificity, and predictive value of modified assays for activated protein C resistance in children. Thromb Haemost. 1998;79:567-570.
17. Falk G, Almqvist A, Nordemhem A, Svensson H, Wiman B. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis. 1995;9: 170-174.
18. Frosst P, Blom HJ,. Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
19. Glueck CJ, Brandt G, Gruppo R, et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop. 1997;338:139-152.
20. Kluijtmans LA, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
21. Newton CR, Graham A, Hepinstall LE, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503-2516.
22. Glueck CJ, Crawford A, Roy D, Freiberg R, Glueck H, Stroop D. Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease. J Bone Joint Surg Am. 1996;78:3-13.
23. Glueck CJ, Glueck HI, Tracy T, Speirs J, McCray C, Stroop D. Relationship between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism. 1993;42:236-246.
24. Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 1995;75:132-136.
25. Glueck CJ, Fontaine RN, Gupta A, Tracy T, Wang P. Familial 4G4G homozygosity in the plasminogen activator inhibitor gene promotor, hyperinsulinemia, thrombosis, and osteonecrosis. J Invest Med. 1997;45:331A.
26. Gruppo R, Glueck CJ, McMahon RE, et al. Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis: pathophysiology of osteonecrosis of the jaw. J Lab Clin Med. 1996;127:481-489.
27. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames: Iowa State University Press; 1980.
28. Glueck CJ, Lang JE. Lipoprotein metabolism in the elderly. In: Abrams WB, Beers MH, Berkow RB, eds. Merck Manual of Geriatrics. Rahway. NJ: Merck & Co; 1995: 1023-1052.
29. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thmmb Haemost. 1997;78:1-6.
30. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
31. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest. 1990;85:1709-1715.
32. Edelberg JM, Pizzo SV. Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner. Blood Coagul Fibrinolysis. 1991;2:759-764.
33. Pekelharing HLM, Kleinveld HA, Duif PFCCM, Bouma BN, van Rijn HJM. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost. 1996;75:497-502.
34. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem. 1991;266:2459-2465.
35. Fong AC, Schatz H, McDonald HR, et al. Central retinal vein occlusion in young adults (papillophlebitis). Retina. 1992;12:3-11.
36. Walters RF, Spalton DJ. Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients. Br J Ophthalmol. 1990;74:30-35.
37. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol. 1993;37:393-417.
38. Priluck IA, Robertson DM, Hollenhorst RW. Long-term follow-up of occlusion of the central retinal vein in young adults. Am J Ophthalmol. 1980;90:190-202.
39. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.